Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with
 sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Pulmonary sarcoidosis-associated pulmonary hypertension is classified as WHO Group 5
 pulmonary hypertension and may occur in anywhere from 5-20% of sarcoidosis patients. Inhaled
 treprostinil has shown clinical improvements in exercise capacity after 12 weeks of therapy
 in patients with WHO Group 1 pulmonary hypertension. More recently, there has been interest
 in using inhaled PAH-specific therapies for the treatment of pulmonary hypertension
 associated with interstitial lung disease.

 The investigators believe that those patients with pulmonary hypertension in the setting of
 sarcoidosis-associated interstitial lung disease are a unique population which may
 potentially benefit from inhaled, targeted pulmonary arterial hypertension therapy (inhaled
 treprostinil) while minimizing the adverse effects associated with systemic pulmonary
 vasodilators. This study aims to evaluate the efficacy and safety of inhaled treprostinil in
 subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Inclusion Criteria:

 -  Study participant willing and able to provide informed consent

 -  Negative urine pregnancy test at baseline for females of childbearing potential

 -  Established diagnosis of sarcoidosis by ATS/ERS/WASOG 1999 Statement on of Sarcoidosis

 -  Presence of interstitial lung disease by Scadding Stage IV chest radiograph or
 extensive fibrosis on chest computed tomography

 -  Right heart catheterization within six months of baseline visit showing precapillary
 pulmonary hypertension (mPAP ≥ 25 mmHg, PCWP ≤ 15 mmHg, and PVR > 3 WU)

 -  Patient on stable sarcoidosis therapy for at least three months prior to screening

 -  If patients are on oral PAH therapy (PDE5i/SCGS and/or ERA) then dose should be stable
 for at least three months prior to screening

 -  A 6MWT within three months of screening visit of > 100 meters

 Exclusion Criteria:

 -  Pregnant patients or those who are actively lactating

 -  Patient not willing to use form of birth control (if applicable) during the study

 -  Inability to undergo 6MWT, RHC, PFTs or CMRI

 -  Predicted survival < 6 months

 -  Patient on any prostanoid or prostanoid analog therapy

 -  Patients with left sided heart disease as defined by either a PCWP > 15 mmHg and/or
 left ventricular ejection fraction < 40%

 -  Use of any investigational drug/device, or participation in any investigational study
 with therapeutic intent within 30 days prior to randomization.